Top Markets
#1 Akedo Akedo +57.11%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +49.98%
#4 Velvet Velvet +42.35%
#5 Black Phoenix Black Phoenix +34.56%
#6 Ο„emplar Ο„emplar +28.04%
#7 Ribbita by Virtuals Ribbita by Virtuals +19.92%
#8 Bitway Bitway +17.09%
#9 Not in Employment, Education, or Training Not in Employment, Education, or Training +16.98%
#10 Cap Cap +16.13%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
CohBar, Inc. CohBar, Inc.

CohBar, Inc.

CWBR
Rank in Stocks #38304
CohBar Inc. is a clinical-stage biotechnology company dedicated to the... CohBar Inc. is a clinical-stage biotechnology company dedicated to the discovery and advancement of therapies that leverage mitochondrial biology, known as mitochondria-based therapeutics (MBTs). Their primary objective is to combat chronic conditions and diseases associated with aging. These MBTs are being developed to address a broad spectrum of medical challenges, including non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis (IPF), type 2 diabetes, acute respiratory distress syndrome (ARDS), various cancers, and cardiovascular disorders like Alzheimer's disease. Their flagship clinical asset is CB4211, an innovative, optimized analogue of the MOTS-c mitochondrial-derived peptide. This candidate is currently undergoing Phase Ib evaluation as part of a larger Phase Ia/Ib clinical trial, specifically targeting non-alcoholic steatohepatitis (NASH) and obesity. Beyond their clinical work, CohBar's preclinical portfolio features CB5138 analogs aimed at fibrotic conditions, as well as CB5064 analogs being explored for their potential in treating ARDS linked to COVID-19. Established in 2007, CohBar, Inc. maintains its corporate headquarters in Menlo Park, California.
Share Price
$0.41
Last synced: 2025-01-23
Market Cap
$1.08M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade CohBar, Inc. (CWBR)

Category

Healthcare
Operating Margin for CohBar, Inc. (CWBR)
Operating Margin as of August 2026 TTM: 0.00%
According to CohBar, Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2021 the company had an Operating Margin of 0.00%.
Operating Margin history for CohBar, Inc. from 2011 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
2015 0.00% 0.00%
2014 0.00% 0.00%
2013 0.00% 0.00%
2012 0.00% 0.00%
2011 0.00% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.97% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00% -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
31.23% -
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.